首页 > 最新文献

European Heart Journal最新文献

英文 中文
Xylitol exposure and cardiovascular risk. 接触木糖醇与心血管风险
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-20 DOI: 10.1093/eurheartj/ehae730
Bettina K Wölnerhanssen, Anne Christin Meyer-Gerspach, Arduino Arduini
{"title":"Xylitol exposure and cardiovascular risk.","authors":"Bettina K Wölnerhanssen, Anne Christin Meyer-Gerspach, Arduino Arduini","doi":"10.1093/eurheartj/ehae730","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae730","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated serum xylitol levels and cardiovascular risk: an active component or an innocent bystander? 血清木糖醇水平升高与心血管风险:是活性成分还是无辜的旁观者?
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-20 DOI: 10.1093/eurheartj/ehae731
Mario Bonomini, Valentina Masola, Edoardo Gronda
{"title":"Elevated serum xylitol levels and cardiovascular risk: an active component or an innocent bystander?","authors":"Mario Bonomini, Valentina Masola, Edoardo Gronda","doi":"10.1093/eurheartj/ehae731","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae731","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First past the post: research on endurance exercise wins the Desmond Julian Award. 第一个过去:耐力锻炼研究荣获德斯蒙德-朱利安奖。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-19 DOI: 10.1093/eurheartj/ehae750
Judith Ozkan
{"title":"First past the post: research on endurance exercise wins the Desmond Julian Award.","authors":"Judith Ozkan","doi":"10.1093/eurheartj/ehae750","DOIUrl":"10.1093/eurheartj/ehae750","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden. 设备检测到的心房颤动的中风风险受血管疾病负担连续性的影响。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-19 DOI: 10.1093/eurheartj/ehae797
Dominik Linz, Sevasti-Maria Chaldoupi
{"title":"Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden.","authors":"Dominik Linz, Sevasti-Maria Chaldoupi","doi":"10.1093/eurheartj/ehae797","DOIUrl":"10.1093/eurheartj/ehae797","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention. STOPDAPT-3 一年期结果支持经皮冠状动脉介入治疗后阿司匹林和氯吡格雷具有相似的疗效和安全性。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-19 DOI: 10.1093/eurheartj/ehae773
Rocco Vergallo, Carlo Patrono
{"title":"STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention.","authors":"Rocco Vergallo, Carlo Patrono","doi":"10.1093/eurheartj/ehae773","DOIUrl":"10.1093/eurheartj/ehae773","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defibrillation and refractory ventricular fibrillation. 除颤和难治性心室颤动。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-18 DOI: 10.1093/eurheartj/ehae767
Bas J Verkaik, Robert G Walker, Tyson G Taylor, Mette M Ekkel, Rob Marx, Remy Stieglis, Vera G M van Eeden, Lotte C Doeleman, Michiel Hulleman, Fred W Chapman, Hans van Schuppen, Christian van der Werf
{"title":"Defibrillation and refractory ventricular fibrillation.","authors":"Bas J Verkaik, Robert G Walker, Tyson G Taylor, Mette M Ekkel, Rob Marx, Remy Stieglis, Vera G M van Eeden, Lotte C Doeleman, Michiel Hulleman, Fred W Chapman, Hans van Schuppen, Christian van der Werf","doi":"10.1093/eurheartj/ehae767","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae767","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. 更正:蒽环类药物诱发的心血管毒性:心力衰竭协会和国际心肿瘤协会风险评分的验证。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-18 DOI: 10.1093/eurheartj/ehae818
{"title":"Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.","authors":"","doi":"10.1093/eurheartj/ehae818","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae818","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study. 静脉血栓栓塞后使用非甾体抗炎药和抗凝剂的出血风险:一项全国性的丹麦研究。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-18 DOI: 10.1093/eurheartj/ehae736
Søren Riis Petersen, Kasper Bonnesen, Erik Lerkevang Grove, Lars Pedersen, Morten Schmidt

Background and aims: The bleeding risk of using non-steroidal anti-inflammatory drugs (NSAIDs) in patients treated with oral anticoagulants for venous thromboembolism (VTE) remains unclear.

Methods: A nationwide cohort study of 51 794 VTE patients initiating oral anticoagulants between 1 January 2012 and 31 December 2022 was conducted. Time-dependent multivariate cause-specific Cox regression was used to compute adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes.

Results: Event rates for any bleeding per 100 person-years were 3.5 [95% confidence interval (CI), 3.4-3.7] during periods without NSAID use and 6.3 (95% CI, 5.1-7.9) during periods with NSAID use (number needed to harm = 36 patients treated for 1 year). Compared with non-use, the adjusted hazard ratios for any bleeding associated with NSAID use were 2.09 (95% CI, 1.67-2.62) overall, 1.79 (95% CI, 1.36-2.36) for ibuprofen, 3.30 (95% CI, 1.82-5.97) for diclofenac, and 4.10 (95% CI, 2.13-7.91) for naproxen. Compared with non-use, the adjusted hazard ratios associated with NSAID use were 2.24 (95% CI, 1.61-3.11) for gastrointestinal bleeding, 3.22 (95% CI, 1.69-6.14) for intracranial bleeding, 1.36 (95% CI, .67-2.77) for thoracic and respiratory tract bleeding, 1.57 (95% CI, .98-2.51) for urinary tract bleeding, and 2.99 (95% CI, 1.45-6.18) for anaemia caused by bleeding. Results were consistent for anticoagulant and VTE subtypes.

Conclusions: Patients treated with oral anticoagulants for VTE had a more than two-fold increased bleeding rate when using NSAIDs. This increased bleeding rate was not restricted to the gastrointestinal tract.

背景和目的:静脉血栓栓塞症(VTE)口服抗凝药物治疗患者使用非甾体抗炎药(NSAID)的出血风险仍不明确:对2012年1月1日至2022年12月31日期间开始口服抗凝药的51 794名VTE患者进行了全国性队列研究。采用时间依赖性多变量特定病因 Cox 回归计算非甾体抗炎药使用与医院诊断出血发作之间的调整后危险比:在未使用非甾体抗炎药期间,每 100 人年的任何出血事件发生率为 3.5 [95% 置信区间 (CI),3.4-3.7];在使用非甾体抗炎药期间,每 100 人年的任何出血事件发生率为 6.3 (95% CI,5.1-7.9)(伤害所需人数 = 36 名接受 1 年治疗的患者)。与不使用相比,与使用非甾体抗炎药相关的任何出血的调整后危险比总体为 2.09(95% CI,1.67-2.62),布洛芬为 1.79(95% CI,1.36-2.36),双氯芬酸为 3.30(95% CI,1.82-5.97),萘普生为 4.10(95% CI,2.13-7.91)。与不使用相比,使用非甾体抗炎药与胃肠道出血的调整后危险比为 2.24(95% CI,1.61-3.11),与颅内出血的调整后危险比为 3.22(95% CI,1.69-6.14),与胃肠道出血的调整后危险比为 1.36(95% CI,0.67-2.77),泌尿道出血为 1.57(95% CI,0.98-2.51),出血引起的贫血为 2.99(95% CI,1.45-6.18)。抗凝剂和 VTE 亚型的结果一致:结论:使用口服抗凝剂治疗 VTE 的患者在使用非甾体抗炎药时出血率增加了两倍多。这种出血率的增加并不局限于胃肠道。
{"title":"Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study.","authors":"Søren Riis Petersen, Kasper Bonnesen, Erik Lerkevang Grove, Lars Pedersen, Morten Schmidt","doi":"10.1093/eurheartj/ehae736","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae736","url":null,"abstract":"<p><strong>Background and aims: </strong>The bleeding risk of using non-steroidal anti-inflammatory drugs (NSAIDs) in patients treated with oral anticoagulants for venous thromboembolism (VTE) remains unclear.</p><p><strong>Methods: </strong>A nationwide cohort study of 51 794 VTE patients initiating oral anticoagulants between 1 January 2012 and 31 December 2022 was conducted. Time-dependent multivariate cause-specific Cox regression was used to compute adjusted hazard ratios between NSAID use and hospital-diagnosed bleeding episodes.</p><p><strong>Results: </strong>Event rates for any bleeding per 100 person-years were 3.5 [95% confidence interval (CI), 3.4-3.7] during periods without NSAID use and 6.3 (95% CI, 5.1-7.9) during periods with NSAID use (number needed to harm = 36 patients treated for 1 year). Compared with non-use, the adjusted hazard ratios for any bleeding associated with NSAID use were 2.09 (95% CI, 1.67-2.62) overall, 1.79 (95% CI, 1.36-2.36) for ibuprofen, 3.30 (95% CI, 1.82-5.97) for diclofenac, and 4.10 (95% CI, 2.13-7.91) for naproxen. Compared with non-use, the adjusted hazard ratios associated with NSAID use were 2.24 (95% CI, 1.61-3.11) for gastrointestinal bleeding, 3.22 (95% CI, 1.69-6.14) for intracranial bleeding, 1.36 (95% CI, .67-2.77) for thoracic and respiratory tract bleeding, 1.57 (95% CI, .98-2.51) for urinary tract bleeding, and 2.99 (95% CI, 1.45-6.18) for anaemia caused by bleeding. Results were consistent for anticoagulant and VTE subtypes.</p><p><strong>Conclusions: </strong>Patients treated with oral anticoagulants for VTE had a more than two-fold increased bleeding rate when using NSAIDs. This increased bleeding rate was not restricted to the gastrointestinal tract.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding. 口服抗凝药和非甾体抗炎药:出血的秘诀。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-18 DOI: 10.1093/eurheartj/ehae795
William A E Parker, Robert F Storey
{"title":"Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding.","authors":"William A E Parker, Robert F Storey","doi":"10.1093/eurheartj/ehae795","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae795","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification. 动脉粥样斑块转录组学发现 ARNTL 是一种平滑肌细胞调控因子,它与临床和基因数据一起改善了风险分层。
IF 37.6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-18 DOI: 10.1093/eurheartj/ehae768
Sampath Narayanan, Sofija Vuckovic, Otto Bergman, Robert Wirka, Jose Verdezoto Mosquera, Qiao Sen Chen, Damiano Baldassarre, Elena Tremoli, Fabrizio Veglia, Mariette Lengquist, Redouane Aherahrrou, Anton Razuvaev, Bruna Gigante, Hanna M Björck, Clint L Miller, Thomas Quertermous, Ulf Hedin, Ljubica Matic

Background and aims: The role of vascular smooth muscle cells (SMCs) in atherosclerosis has evolved to indicate causal genetic links with the disease. Single cell RNA sequencing (scRNAseq) studies have identified multiple cell populations of mesenchymal origin within atherosclerotic lesions, including various SMC sub-phenotypes, but it is unknown how they relate to patient clinical parameters and genetics. Here, mesenchymal cell populations in atherosclerotic plaques were correlated with major coronary artery disease (CAD) genetic variants and functional analyses performed to identify SMC markers involved in the disease.

Methods: Bioinformatic deconvolution was done on bulk microarrays from carotid plaques in the Biobank of Karolinska Endarterectomies (BiKE, n = 125) using public plaque scRNAseq data and associated with patient clinical data and follow-up information. BiKE patients were clustered based on the deconvoluted cell fractions. Quantitative trait loci (QTLs) analyses were performed to predict the effect of CAD associated genetic variants on mesenchymal cell fractions (cfQTLs) and gene expression (eQTLs) in plaques.

Results: Lesions from symptomatic patients had higher fractions of Type 1 macrophages and pericytes, but lower fractions of classical and modulated SMCs compared with asymptomatic ones, particularly females. Presence of diabetes or statin treatment did not affect the cell fraction distribution. Clustering based on plaque cell fractions, revealed three patient groups, with relative differences in their stability profiles and associations to stroke, even during long-term follow-up. Several single nucleotide polymorphisms associated with plaque mesenchymal cell fractions, upstream of the circadian rhythm gene ARNTL were identified. In vitro silencing of ARNTL in human carotid SMCs increased the expression of contractile markers and attenuated cell proliferation.

Conclusions: This study shows the potential of combining scRNAseq data with vertically integrated clinical, genetic, and transcriptomic data from a large biobank of human plaques, for refinement of patient vulnerability and risk prediction stratification. The study revealed novel CAD-associated variants that may be functionally linked to SMCs in atherosclerotic plaques. Specifically, variants in the ARNTL gene may influence SMC ratios and function, and its role as a regulator of SMC proliferation should be further investigated.

背景和目的:血管平滑肌细胞(SMC)在动脉粥样硬化中的作用已逐渐显示出与该疾病的因果遗传联系。单细胞 RNA 测序(scRNAseq)研究发现了动脉粥样硬化病变中的多种间充质细胞群,包括各种 SMC 亚型,但它们与患者临床参数和遗传之间的关系尚不清楚。在这里,动脉粥样硬化斑块中的间充质细胞群与主要冠状动脉疾病(CAD)遗传变异相关,并进行了功能分析,以确定参与疾病的SMC标记物:利用公开的斑块scRNAseq数据,并结合患者的临床数据和随访信息,对来自卡罗林斯卡内膜切除术生物库(BiKE,n = 125)颈动脉斑块的批量微阵列进行了生物信息学解卷积。根据去卷积细胞组分对 BiKE 患者进行分组。进行了定量性状位点(QTLs)分析,以预测CAD相关基因变异对斑块中间质细胞组分(cfQTLs)和基因表达(eQTLs)的影响:与无症状患者(尤其是女性)相比,有症状患者的病变中1型巨噬细胞和周细胞的比例较高,但经典和调制间充质细胞的比例较低。糖尿病或他汀类药物治疗并不影响细胞的分布。根据斑块细胞分布情况进行的聚类分析显示,有三组患者的稳定性和与中风的相关性存在相对差异,即使在长期随访期间也是如此。在昼夜节律基因ARNTL的上游发现了几个与斑块间质细胞组分相关的单核苷酸多态性。体外沉默人颈动脉间充质细胞中的 ARNTL 会增加收缩标志物的表达并减少细胞增殖:这项研究表明,将 scRNAseq 数据与来自大型人类斑块生物库的纵向整合临床、遗传和转录组数据相结合,可用于完善患者脆弱性和风险预测分层。该研究揭示了可能与动脉粥样硬化斑块中的SMCs功能相关的新型CAD相关变异。具体来说,ARNTL基因中的变异可能会影响SMC的比例和功能,其作为SMC增殖调节因子的作用有待进一步研究。
{"title":"Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification.","authors":"Sampath Narayanan, Sofija Vuckovic, Otto Bergman, Robert Wirka, Jose Verdezoto Mosquera, Qiao Sen Chen, Damiano Baldassarre, Elena Tremoli, Fabrizio Veglia, Mariette Lengquist, Redouane Aherahrrou, Anton Razuvaev, Bruna Gigante, Hanna M Björck, Clint L Miller, Thomas Quertermous, Ulf Hedin, Ljubica Matic","doi":"10.1093/eurheartj/ehae768","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae768","url":null,"abstract":"<p><strong>Background and aims: </strong>The role of vascular smooth muscle cells (SMCs) in atherosclerosis has evolved to indicate causal genetic links with the disease. Single cell RNA sequencing (scRNAseq) studies have identified multiple cell populations of mesenchymal origin within atherosclerotic lesions, including various SMC sub-phenotypes, but it is unknown how they relate to patient clinical parameters and genetics. Here, mesenchymal cell populations in atherosclerotic plaques were correlated with major coronary artery disease (CAD) genetic variants and functional analyses performed to identify SMC markers involved in the disease.</p><p><strong>Methods: </strong>Bioinformatic deconvolution was done on bulk microarrays from carotid plaques in the Biobank of Karolinska Endarterectomies (BiKE, n = 125) using public plaque scRNAseq data and associated with patient clinical data and follow-up information. BiKE patients were clustered based on the deconvoluted cell fractions. Quantitative trait loci (QTLs) analyses were performed to predict the effect of CAD associated genetic variants on mesenchymal cell fractions (cfQTLs) and gene expression (eQTLs) in plaques.</p><p><strong>Results: </strong>Lesions from symptomatic patients had higher fractions of Type 1 macrophages and pericytes, but lower fractions of classical and modulated SMCs compared with asymptomatic ones, particularly females. Presence of diabetes or statin treatment did not affect the cell fraction distribution. Clustering based on plaque cell fractions, revealed three patient groups, with relative differences in their stability profiles and associations to stroke, even during long-term follow-up. Several single nucleotide polymorphisms associated with plaque mesenchymal cell fractions, upstream of the circadian rhythm gene ARNTL were identified. In vitro silencing of ARNTL in human carotid SMCs increased the expression of contractile markers and attenuated cell proliferation.</p><p><strong>Conclusions: </strong>This study shows the potential of combining scRNAseq data with vertically integrated clinical, genetic, and transcriptomic data from a large biobank of human plaques, for refinement of patient vulnerability and risk prediction stratification. The study revealed novel CAD-associated variants that may be functionally linked to SMCs in atherosclerotic plaques. Specifically, variants in the ARNTL gene may influence SMC ratios and function, and its role as a regulator of SMC proliferation should be further investigated.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":37.6,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Heart Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1